Tianjin Ringpu Bio-Technology Co.,Ltd.

SZSE:300119 Stock Report

Market Cap: CN¥8.8b

Tianjin Ringpu Bio-TechnologyLtd Future Growth

Future criteria checks 2/6

Tianjin Ringpu Bio-TechnologyLtd is forecast to grow earnings and revenue by 18.3% and 15.9% per annum respectively. EPS is expected to grow by 16.4% per annum. Return on equity is forecast to be 10.9% in 3 years.

Key information

18.3%

Earnings growth rate

16.4%

EPS growth rate

Pharmaceuticals earnings growth18.8%
Revenue growth rate15.9%
Future return on equity10.9%
Analyst coverage

Good

Last updated17 Dec 2024

Recent future growth updates

Tianjin Ringpu Bio-Technology Co.,Ltd. Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Aug 26
Tianjin Ringpu Bio-Technology Co.,Ltd. Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Recent updates

There's No Escaping Tianjin Ringpu Bio-Technology Co.,Ltd.'s (SZSE:300119) Muted Earnings Despite A 29% Share Price Rise

Nov 26
There's No Escaping Tianjin Ringpu Bio-Technology Co.,Ltd.'s (SZSE:300119) Muted Earnings Despite A 29% Share Price Rise

Is There An Opportunity With Tianjin Ringpu Bio-Technology Co.,Ltd.'s (SZSE:300119) 42% Undervaluation?

Nov 25
Is There An Opportunity With Tianjin Ringpu Bio-Technology Co.,Ltd.'s (SZSE:300119) 42% Undervaluation?

Solid Earnings May Not Tell The Whole Story For Tianjin Ringpu Bio-TechnologyLtd (SZSE:300119)

Nov 05
Solid Earnings May Not Tell The Whole Story For Tianjin Ringpu Bio-TechnologyLtd (SZSE:300119)

These 4 Measures Indicate That Tianjin Ringpu Bio-TechnologyLtd (SZSE:300119) Is Using Debt Reasonably Well

Oct 30
These 4 Measures Indicate That Tianjin Ringpu Bio-TechnologyLtd (SZSE:300119) Is Using Debt Reasonably Well

The Market Lifts Tianjin Ringpu Bio-Technology Co.,Ltd. (SZSE:300119) Shares 36% But It Can Do More

Oct 08
The Market Lifts Tianjin Ringpu Bio-Technology Co.,Ltd. (SZSE:300119) Shares 36% But It Can Do More

Tianjin Ringpu Bio-Technology Co.,Ltd. Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Aug 26
Tianjin Ringpu Bio-Technology Co.,Ltd. Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Improved Earnings Required Before Tianjin Ringpu Bio-Technology Co.,Ltd. (SZSE:300119) Shares Find Their Feet

Aug 23
Improved Earnings Required Before Tianjin Ringpu Bio-Technology Co.,Ltd. (SZSE:300119) Shares Find Their Feet

Tianjin Ringpu Bio-TechnologyLtd (SZSE:300119) Seems To Use Debt Quite Sensibly

Jun 26
Tianjin Ringpu Bio-TechnologyLtd (SZSE:300119) Seems To Use Debt Quite Sensibly

Impressive Earnings May Not Tell The Whole Story For Tianjin Ringpu Bio-TechnologyLtd (SZSE:300119)

Apr 05
Impressive Earnings May Not Tell The Whole Story For Tianjin Ringpu Bio-TechnologyLtd (SZSE:300119)

Tianjin Ringpu Bio-Technology Co.,Ltd.'s (SZSE:300119) Subdued P/E Might Signal An Opportunity

Mar 28
Tianjin Ringpu Bio-Technology Co.,Ltd.'s (SZSE:300119) Subdued P/E Might Signal An Opportunity

Earnings and Revenue Growth Forecasts

SZSE:300119 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20263,4646185356347
12/31/20253,0765421675598
12/31/20242,6144231684568
9/30/20242,409424326537N/A
6/30/20242,354434186437N/A
3/31/20242,339460196438N/A
12/31/20232,249453134378N/A
9/30/20232,195387129386N/A
6/30/20232,170385156462N/A
3/31/20232,136355139473N/A
1/1/20232,08434717389N/A
9/30/20221,985354-1367N/A
6/30/20221,8753490317N/A
3/31/20221,838369-41287N/A
1/1/20222,00741377383N/A
9/30/20212,03843872358N/A
6/30/20212,11745487408N/A
3/31/20212,106441134438N/A
12/31/20202,000398129388N/A
9/30/20201,895302175460N/A
6/30/20201,737255183417N/A
3/31/20201,613224190396N/A
12/31/20191,467194154384N/A
9/30/20191,34615883264N/A
6/30/20191,26013756216N/A
3/31/20191,20312432167N/A
12/31/20181,19011962175N/A
9/30/20181,17910840155N/A
6/30/20181,157117N/A159N/A
3/31/20181,112112N/A113N/A
12/31/20171,047105N/A110N/A
9/30/20171,008136N/A152N/A
6/30/2017993138N/A155N/A
3/31/2017988140N/A185N/A
12/31/2016970133N/A208N/A
9/30/2016943129N/A214N/A
6/30/2016905113N/A221N/A
3/31/2016832108N/A223N/A
12/31/2015793110N/A225N/A
9/30/201569068N/A172N/A
6/30/201563943N/A131N/A
3/31/201562534N/A140N/A
12/31/201458527N/A130N/A
9/30/201466995N/A138N/A
6/30/2014676113N/A136N/A
3/31/2014722140N/A116N/A
12/31/2013755152N/A89N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 300119's forecast earnings growth (18.3% per year) is above the savings rate (2.8%).

Earnings vs Market: 300119's earnings (18.3% per year) are forecast to grow slower than the CN market (25.7% per year).

High Growth Earnings: 300119's earnings are forecast to grow, but not significantly.

Revenue vs Market: 300119's revenue (15.9% per year) is forecast to grow faster than the CN market (13.7% per year).

High Growth Revenue: 300119's revenue (15.9% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 300119's Return on Equity is forecast to be low in 3 years time (10.9%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/19 05:07
End of Day Share Price 2024/12/19 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Tianjin Ringpu Bio-Technology Co.,Ltd. is covered by 19 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jia ChenChangjiang Securities Co. LTD.
Xu Qing LiuChasing Securities
Junhao FanChina International Capital Corporation Limited